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• Determine whether the implementation of the recently 
implemented MRSA nasal swab protocol translates to a 
decrease in the vancomycin-associated acute kidney injury 
(AKI), length of stay and associated-cost 
• Compare the incidence of AKI with the combination of 
piperacillin/tazobactam (Zosyn) and vancomycin versus 
cefepime and vancomycin 
• Study design: Single-center, quasi experimental study, 
involving patients receiving empiric anti-MRSA therapy with 
vancomycin for CAP at Homestead Hospital 
• Inclusion criteria: 
• Patients ≥ 18 years old 
• Patients in which vancomycin is initiated within 48 hours 
of hospital admission for the treatment of CAP from 
November 1st, 2019 to March 31st, 2021
• Exclusion criteria: 
• Patients < 18 years old 
• Pregnant patients 
• Patients receiving vancomycin for indications other than 
CAP 
• Patients in which vancomycin is initiated more than 48 
hours after hospital admission 
• Patients with structural lung disease (e.g. cystic fibrosis or 
bronchiectasis)
• Pneumonia caused by Methicillin-resistant Staphylococcus 
aureus (MRSA) has been linked to a high incidence of 
morbidity and mortality1
• However, the concern associated with possible MRSA 
pneumonia has contributed to an overutilization of empiric 
anti-MRSA therapy that potentiates unfavorable outcomes 2,3
• The 2019 Community Acquired Pneumonia (CAP) guidelines 
recommend patients with prior respiratory isolation for MRSA, 
or recent hospitalization requiring intravenous antibiotics may 
receive empiric anti-MRSA coverage until the results of a 
polymerase chain reaction (PCR) nasal culture are available
• Based on the substantial data supporting the utilization of this 
tool, Homestead Hospital developed a protocol allowing 
pharmacists to order the rapid nasal swab test for possible 






• Anticipated completion date April 30, 2021
LIMITATIONS
• Small sample size
• Disproportionate number of patients receiving Zosyn versus 
Cefepime
• Difficult to assess cost at the different units throughout the 
hospital
REFERENCES
1. Dangerfield B, Chung A, Webb B, Seville MT. Predictive value 
of methicillin-resistant Staphylococcus aureus (MRSA) nasal 
swab PCR assay for MRSA pneumonia. Antimicrob Agents 
Chemother. 2014;58(2):859-864. 
2. Minejima E, Lou M, Nieberg P, Wong-Beringer A. Patients 
presenting to the hospital with MRSA pneumonia: 
differentiating characteristics and outcomes with empiric 
treatment. BMC Infect Dis. 2014;14:252. Published 2014 
May 10. 
3. Parente DM, Cunha CB, Mylonakis E, Timbrook TT. The 
Clinical Utility of Methicillin-Resistant Staphylococcus aureus 
(MRSA) Nasal Screening to Rule Out MRSA Pneumonia: A 
Diagnostic Meta-analysis With Antimicrobial Stewardship 
Implications. Clin Infect Dis. 2018;67(1):1-7.
4. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and 
Treatment of Adults with Community-acquired Pneumonia. 
An Official Clinical Practice Guideline of the American 
Thoracic Society and Infectious Diseases Society of America. 
Am J Respir Crit Care Med. 2019;200(7):e45-e67. 
doi:10.1164/rccm.201908-1581ST
DISCUSSION




Female, n (%) 26 (50%)
Male, n (%) 26 (50.%)
Age (In Years)
Mean (SD) 66.6 (15.8)
• Procedure:
• A retrospective chart review was conducted in 65 patients who received vancomycin 
due to  a pneumonia indication
• Data was collected to assess the incidence of  vancomycin-associated AKI, length of 
stay, associated-cost,  and t  compare the rate of occurrence of AKI with the 
combination of v ncomycin and Zosyn versus v ncom cin and c fepime 
• AKI was defined utilizing the Kidney Disease: Improving Global Outcomes (KDIGO) 
clinical practice guideline criteria*
Pre-implementation of the Protocol
• Study in progress 




• 4.7 days •$5,508
Average cost 




























Pre-Implementation of the Protocol 

















▴Excluded patients: No CAP diagnosis, n=11
Vancomycin initiated > 48 hours after hospital admission, n=2 
